skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Merestinib (Code C95729)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Merestinib

Definition: An orally available, small molecule inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Merestinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. This agent has potent anti-tumor efficacy in mono and combination therapy in a broad range of cancers. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.

Display Name: Merestinib

Label: Merestinib

NCI Thesaurus Code: C95729 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2987379  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
3-Pyridinecarboxamide, N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-1,2-dihydro-6-methyl-2-oxo-

External Source Codes: 
CAS Registry Number 1206799-15-6 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 694732
PDQ Open Trial Search ID 694732 (check for NCI PDQ open clinical trial info)
UMLS CUI C2987379

Other Properties:
     Name Value (qualifiers indented underneath)
code C95729
Contributing_Source CTRP
Contributing_Source FDA
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom